Treatment of hyperlipidemia: guideline update highlights
Can you elaborate a resume, update highlights for internal medicine providers to treat hyperlipidemia segun la nueva guia AHA 2026
Summary
The 2026 ACC/AHA multisociety Guideline on the Management of Dyslipidemia replaces the 2018 cholesterol guideline and broadens management beyond LDL-C to include non-HDL-C, triglyceride-rich remnants, lipoprotein(a) [Lp(a)], and apolipoprotein B (ApoB) [1]. The principal practical changes for internal medicine are: use PREVENT-ASCVD rather than the pooled cohort equations for primary prevention, measure Lp(a) at least once in adulthood, selectively use ApoB and coronary artery calcium (CAC), and return to explicit LDL-C and non-HDL-C treatment goals. Secondary prevention is now more target-based, with LDL-C <55 mg/dL and non-HDL-C <85 mg/dL for patients at very high ASCVD risk. Lifestyle therapy and statins remain foundational; nonstatin treatment is added when risk-based targets are not reached or when statins are not tolerated.
1. What changed from the 2018 approach?
A. Risk assessment: replace the Pooled Cohort Equations with PREVENT-ASCVD
For adults aged 30–79 years without established ASCVD, the guideline recommends the AHA PREVENT-ASCVD equations for estimating 10-year risk and, when appropriate, 30-year risk. The recommended clinical approach is:
- Calculate risk with PREVENT-ASCVD.
- Personalize the estimate using clinical factors not fully captured by the equation.
- Reclassify selectively with CAC scoring when the treatment decision remains uncertain. [1]
In primary prevention:
- Lipid-lowering therapy may be considered when 10-year risk is 3% to <5%.
- Therapy should be considered when 10-year risk is 5% to <10%, following clinician–patient discussion.
- Risk assessment should not be used mechanically; diabetes, CKD, family history, inflammatory disease, Lp(a), ApoB, triglycerides, and other risk modifiers can alter the treatment discussion. [1]
The 2026 guideline therefore moves away from a purely threshold-based interpretation of a single 10-year risk estimate.
B. Treatment goals are explicitly reintroduced
The guideline again uses LDL-C and non-HDL-C goals in addition to the expected percentage reduction from baseline. The percentage reduction remains clinically relevant, particularly when initiating high-intensity statin therapy, but clinicians should also assess whether the patient has reached the appropriate absolute goal.
For secondary prevention:
- Very-high-risk ASCVD: LDL-C goal <55 mg/dL and non-HDL-C goal <85 mg/dL.
- Patients with established ASCVD who do not meet the very-high-risk category generally have a less stringent goal, commonly LDL-C <70 mg/dL, depending on the guideline-defined risk category. [1]
The <55 mg/dL target is especially relevant for patients with recurrent events, polyvascular disease, or other features placing them at very high risk. Direct treatment intensity should be based on the patient’s risk category rather than LDL-C alone.
2. New testing recommendations
A. Lipoprotein(a)
Lp(a) should be measured at least once in every adult’s lifetime. It is genetically determined, relatively stable, and is not routinely reflected in the standard lipid panel.
The guideline identifies:
- Lp(a) ≥125 nmol/L, or ≥50 mg/dL, as a risk-enhancing level.
- Lp(a) ≥250 nmol/L, or ≥100 mg/dL, as a substantially higher-risk phenotype. [1]
Important clinical implications:
- An elevated Lp(a) should prompt more intensive management of LDL-C and all modifiable risk factors.
- Lp(a) is not currently managed by simply repeating measurements or by routine niacin therapy.
- Lp(a) elevation may support earlier pharmacologic treatment or CAC assessment when the primary-prevention decision is uncertain.
- Avoid converting nmol/L to mg/dL with a fixed formula; the relationship depends on apo(a) isoform size.
B. ApoB
ApoB is recommended selectively rather than universally. It may be particularly useful when:
- Triglycerides are >200 mg/dL.
- Diabetes, obesity, or metabolic syndrome may cause LDL-C to underestimate atherogenic particle burden.
- LDL-C is already <70 mg/dL but residual risk is suspected.
- There is discordance between LDL-C, non-HDL-C, triglycerides, and the clinical phenotype.
- A specific lipoprotein disorder is suspected. [1]
ApoB should complement—not automatically replace—LDL-C and non-HDL-C.
C. Coronary artery calcium
CAC can be used selectively to reclassify risk, especially when the decision to start or intensify therapy is uncertain. The guideline highlights use in appropriate men aged ≥40 years and women aged ≥45 years, considering both the absolute CAC score and the age-, sex-, and race-standardized percentile. [1]
A CAC score of zero may support deferral of statin therapy in selected lower-risk adults, but it should not automatically defer treatment in patients with diabetes, significant smoking exposure, strong premature family history, markedly elevated LDL-C, or other compelling indications. CAC is a decision aid, not a substitute for clinical judgment.
3. Who should generally receive pharmacologic therapy?
A. Established ASCVD
Patients with clinical ASCVD should receive maximally tolerated high-intensity statin therapy unless contraindicated. The treatment objective is to achieve the guideline-defined LDL-C goal, not merely a percentage reduction.
For very-high-risk ASCVD, use an LDL-C goal <55 mg/dL. If the goal is not reached:
- Confirm adherence and exclude secondary causes.
- Use maximally tolerated statin therapy.
- Add ezetimibe when additional LDL-C reduction is needed.
- Add a PCSK9-directed therapy when further reduction is required or the patient remains substantially above goal.
- Consider other guideline-supported agents in selected patients, including those with statin intolerance or persistent inadequate response. [1]
There is no basis for assuming that one nonstatin agent is universally superior to another outside the clinical context. Choice should consider LDL-C reduction required, cost, route, adherence, drug interactions, comorbidities, and prior response.
B. Diabetes
For adults aged 40–75 years with diabetes, LDL-lowering therapy is recommended regardless of baseline LDL-C. Treatment intensity should reflect age, diabetes duration, additional risk factors, target-organ damage, CKD, and evidence of ASCVD. [1]
In practice:
- Begin at least moderate-intensity statin therapy for most patients aged 40–75 years with diabetes.
- Use high-intensity therapy when overall risk is higher or a larger LDL-C reduction is appropriate.
- Intensify based on absolute LDL-C goals and risk category.
- Do not use a normal baseline LDL-C as a reason to avoid treatment in a higher-risk patient with diabetes.
C. Chronic kidney disease
For adults aged 40–75 years with CKD stage 3 or 4, LDL-lowering therapy is recommended regardless of LDL-C level. [1] Treatment should be integrated with kidney function, albuminuria, drug interactions, frailty, and the patient’s overall ASCVD risk.
D. Severe primary hypercholesterolemia and familial hypercholesterolemia
Markedly elevated LDL-C, particularly LDL-C ≥190 mg/dL, should prompt evaluation for familial hypercholesterolemia and secondary causes. Treatment should not be delayed while waiting for a calculated risk score, because risk equations are not appropriate substitutes for treatment in this phenotype.
Assess:
- Family history of premature ASCVD.
- Tendon xanthomas or corneal arcus at a young age.
- LDL-C in first-degree relatives.
- Hypothyroidism, nephrotic syndrome, cholestatic liver disease, medications, and dietary contributors.
- Need for specialist referral and cascade screening.
4. Hypertriglyceridemia
Persistent triglyceride elevation should be addressed with both lifestyle intervention and evaluation for secondary causes. Important contributors include uncontrolled diabetes, alcohol, obesity, hypothyroidism, CKD, nephrotic syndrome, pregnancy, and medications such as corticosteroids, estrogens, atypical antipsychotics, some beta-blockers, thiazides, and HIV therapies.
Key points:
- Statins remain the foundation of pharmacologic ASCVD-risk reduction when triglycerides are persistently elevated.
- Lifestyle management includes weight reduction when appropriate, regular physical activity, reduction of refined carbohydrates and added sugars, and limitation or avoidance of alcohol.
- Very high triglycerides require attention to pancreatitis prevention, particularly when triglycerides are ≥1,000 mg/dL.
- At very high levels, a very-low-fat dietary strategy and triglyceride-lowering therapy may be necessary in addition to treatment of the underlying cause. [1]
Do not use triglyceride-lowering therapy as a replacement for indicated LDL-C reduction.
5. Statin intolerance and adverse effects
Before labeling a patient statin-intolerant:
- Document the specific symptoms, timing, dose, and statin involved.
- Check for hypothyroidism, vitamin deficiency when clinically indicated, renal or hepatic disease, drug interactions, and excessive alcohol use.
- Consider rechallenge with a lower dose, a different statin, or intermittent dosing.
- Use the maximally tolerated statin dose rather than abandoning statin therapy after one unsuccessful trial.
- Add nonstatin therapy when LDL-C remains above the appropriate goal.
Routine creatine kinase testing is not necessary in asymptomatic patients. CK should be measured when clinically significant muscle symptoms, weakness, or myopathy is suspected. Transaminases should be checked when clinically indicated and according to the treatment protocol.
6. Practical workflow for an internal medicine visit
Initial evaluation
Obtain:
- Fasting or nonfasting lipid panel, with repeat fasting testing when triglycerides are markedly elevated or results are discordant.
- A1c or glucose assessment when indicated.
- Blood pressure, smoking status, BMI, kidney function, and diabetes status.
- Medication and alcohol review.
- Family history of premature ASCVD or severe hypercholesterolemia.
- Lp(a) once in adulthood.
- ApoB selectively, especially with triglycerides >200 mg/dL or lipid discordance.
Evaluate for secondary causes when LDL-C or triglycerides are unexpectedly elevated.
Treatment decision
- ASCVD: treat aggressively toward the applicable LDL-C and non-HDL-C goals.
- Diabetes or CKD stage 3–4, age 40–75: initiate LDL-lowering therapy regardless of LDL-C.
- LDL-C ≥190 mg/dL: treat as severe hypercholesterolemia and evaluate for FH/secondary causes.
- Primary prevention without a direct indication: use PREVENT-ASCVD, personalize with risk enhancers, and consider CAC when uncertainty remains.
- Elevated Lp(a): intensify control of LDL-C, blood pressure, diabetes, smoking, and other modifiable risks.
- Hypertriglyceridemia: treat secondary causes and lifestyle first, maintain indicated statin therapy, and address pancreatitis risk at very high levels.
Follow-up
Repeat the lipid panel after initiation or dose adjustment to assess adherence and response, then periodically thereafter. The guideline emphasizes ongoing monitoring and adjustment rather than one-time classification. Confirm that the patient is taking the prescribed medication before escalating therapy.
7. Important limitations and implementation cautions
The guideline incorporates evidence available through late 2024, but not every recommendation has the same evidentiary strength. Statin therapy and several nonstatin strategies are supported by cardiovascular outcomes trials, whereas Lp(a), ApoB, and CAC are primarily risk-stratification tools; their use should not be interpreted as proof that treating the biomarker itself improves outcomes.
The most important operational change for primary care is not simply adopting a new LDL-C number. It is integrating:
PREVENT-ASCVD risk → patient-specific risk enhancers → selective CAC → individualized LDL-C/non-HDL-C treatment goals → timely intensification when goals are not reached.
For secondary prevention, particularly very-high-risk ASCVD, the practical message is more direct: use maximally tolerated statin therapy and add evidence-based nonstatin treatment when needed to achieve LDL-C <55 mg/dL and non-HDL-C <85 mg/dL.
Sources
- https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia
- https://newsroom.heart.org/news/accaha-issue-updated-guideline-for-managing-lipids-cholesterol
- https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia/top-things-to-know
- https://professional.heart.org/en/guidelines-statements/2026-accahaaacvprabcacpmadaagsaphaaspcnlapcna-guideline-on-the-management-ofcir0000000000001423
- https://professional.heart.org/en/-/media/PHD-Files-2/Science-News/p/Plain-Language-Summary-2026-Dyslipidemia-Guideline-English.pdf?sc_lang=en
- https://professional.heart.org/en/science-news/-/media/FA050D215557474F80B26E4AE0AF0B02.ashx
- https://www.acc.org/latest-in-cardiology/articles/2026/04/27/19/07/accel-lite-28apr2026
- https://www.acc.org/latest-in-cardiology/articles/2026/05/01/01/new-in-clinical-guidance
- https://www.acc.org/latest-in-cardiology/articles/2026/06/15/14/16/implications-of-the-2026-multisociety-dyslipidemia-guideline
- https://pubmed.ncbi.nlm.nih.gov/42295619/
- https://heartcare.sydney/acc-aha-2026-dyslipidemia-guidelines/
- https://dig.pharmacy.uic.edu/faqs/2026-2/may-2026-faqs/what-are-key-updates-from-the-2026-acc-aha-aacvpr-abc-acpm-ada-ags-apha-aspc-nla-pcna-guideline-on-dyslipidemia-management/
- https://www.cardiologywiki.com/wiki/sources/lipid-aha-2026/
- https://professional.heart.org/en/science-news/-/media/31C986CF6C02449DB2C3A947BA45C271.ashx
- https://www.heart.org/en/-/media/Files/Professional/Quality-Improvement/Lpa/Lpa-Awareness-Day-Webinar.pdf?sc_lang=en
AI-generated answer based on the cited sources. Check the sources before applying it.